Clinical Trial Search

Primary: Area Under the Concentration-time Curve of BI 1467335 in Plasma Over the Time Interval From 0 to 24 Hours After Administration of the First Dose (AUC0-24) — 3.97; 7.88…

Primary: After the First Dose: Area Under the Concentration-time Curve of BI 1467335 Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) of BI 1467335 (After…

Primary: Percentage of Subjects With Drug-related Adverse Events — 22.2; 33.3; 0.0; 0.0 Percentage of subjects

Primary: Alcohol Consumption in Alcohol Self-Administration Trials — 3.02; 2.35 Standard Drink Units (SDU)

Primary: Peak Plasma Concentration (Cmax) of Sertraline — 28.3; 28.8 ng/mL

Primary: Number of Participants With Clinical Safety Laboratory Adverse Events — 2; 5; 4; 2 Participants

Primary: Number of Participants With Clinical Toxicity Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.0 — 2; 0…

Primary: Overall Response Rate (Confirmed) — 1; 1 Participants

Primary: Incidence of Treatment-Emergent Adverse Events — 1; 0; 2; 1 Participants

Primary: Group 1: Observed Maximum Plasma Concentration (Cmax) of Apremilast — 409.96; 267.85; 329.78; 345.11 ng/mL

Primary: Cmax (Maximum Observed Plasma Concentration) — 95.9; 121.6 ng/mL

Primary: Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) Concentration — -0.82; -1.00; -1.61; -1.81 log10 copies/mL

Primary: Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24) — 4300; 5423; 7439; 9046 h*ng/ml

Primary: Measurement of the Safety Lab Parameter Activated Partial Thromboplastin Time (aPTT) — 1.000; 1.000; 1.000; 1.000 aPTT ratio

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A and Part B — 0…